<div id="readability-page-1" class="page"><div id="parent_top_div">In a market shaped by global tensions and shifting sector dynamics, brokerage firm Prabhudas Lilladher (PL Capital) is advising investors to stay grounded—but not passive. At its recent PL Alpha: India View webinar, the firm brought together senior research and advisory voices to decode what lies ahead for Indian equities. The message was clear: brace for volatility, but don’t lose sight of India’s structural strength. According to Amnish Aggarwal, Co-Head – Institutional Equities, the past few weeks have been marked by sharp swings, largely driven by rising geopolitical tensions involving the US, Israel, and Iran. Yet, India has held up relatively well. Policy interventions—such as cuts in oil taxes—have helped cushion immediate shocks. But Aggarwal cautioned that the real impact may still be building beneath the surface. Higher crude prices could trigger second-order effects, pushing inflation higher in the coming months and potentially forcing a reset in growth and earnings expectations. For investors, that means one thing: don’t confuse short-term stability with long-term immunity. Advisory view: Focus on structural themes and stock opportunities: Vikram Kasat, Vikram Kasat (Head –Advisory) From an advisory standpoint, Vikram Kasat, Head – Advisory, highlighted a shift in how capital is being deployed. Instead of broad-based bets, investors—especially HNIs and institutions—are gravitating toward high-conviction, theme-driven opportunities. Key sectors in focus include: <ul> <li> Logistics, powered by e-commerce growth</li> <li> Ethanol, backed by government blending policies</li> <li> Healthcare, offering defensive stability</li> </ul> At the same time, newer-age themes are gaining traction: <ul> <li> Artificial intelligence</li> <li> Robotics</li> <li> Specialized manufacturing</li> </ul> This signals a deeper transition in markets—from cyclical chasing to structural investing. Markets in a Holding Pattern On the technical side, the outlook is more measured. Vaishali Parekh (Technical Research) and Shilpa Rout (Derivatives Research) pointed to a range-bound market, with indices like Nifty moving within a wide band as investors wait for clearer triggers. <ul> <li> Defined support and resistance levels are in play</li> <li> Momentum is selective, not broad-based</li> </ul> Sectorally: Metals, banks, and autos are showing strength Textiles and chemicals may be nearing a turnaround phase In other words, this isn’t a market for blanket bets—it’s a market for precision. Sectoral strategy: Defensive resilience and cyclical recovery plays Throughout the deliberations, the following two-pronged investment strategy emerged as key: Defensive posture in industries like pharmaceuticals and utilities during uncertain times Cyclical play in capital goods, metals, cement, and engineering, especially in case of de-escalation in geopolitics Capital goods, defense, and infra-related sectors remain strong structural growth bets. Cautious optimism amid uncertainty It is important to be careful of international events that may affect issues like inflation, fiscal deficits, and profit margins through their spill-over effects. However, despite some hitches encountered during the discussion, the experts managed to communicate critical aspects of their strategies effectively. PL Capital’s core message to investors is nuanced but actionable: Stay cautious, because global risks—from inflation to fiscal pressures—are real Stay opportunistic, because India’s macro fundamentals remain strong The current market isn’t about aggressive risk-taking or complete withdrawal. It’s about: <ul> <li> Choosing quality over quantity</li> <li> Maintaining diversification</li> <li> Being selective with sectors and themes</li> </ul></div></div>

生物科技 ETF - VanEck Vectors

南方恒生生物科技ETF(QDII)

华夏上证科创板生物医药ETF

在最近的一场网络研讨会上，券商 Prabhudas Lilladher（PL Capital）建议投资者在全球紧张局势影响市场的情况下保持谨慎但又要抓住机会。专家强调关注结构性主题和高信念投资的重要性，特别是在物流、乙醇和医疗保健等行业。他们指出，尽管印度表现出韧性，但原油价格上涨可能会影响通胀和增长预期。市场目前处于区间震荡状态，需要在投资策略上保持精准，双重关注防御性行业和周期性复苏机会。总体而言，信息强调质量重于数量，以及选择性参与特定行业

Where should you invest in 2026? Experts at PL Capital decode the best bets

Business Standard

印度 MSCI ETF - iShares

Avantis Emerging Markets Equity ETF

医疗业 ETF - Vanguard

中国 MSCI ETF - iShares

GX印度精选十强

国泰中证生物医药ETF

SPDR标普新兴市场高股利ETF

安硕印度

华夏印度

华夏医药ETF

iShares MSCI EM Ex-China

Vanguard富时新兴市场指数ETF

2 倍做空纳斯达克生物技术 ETF - ProShares

FIL Ltd.

鹏华上证科创板生物医药ETF

华夏中证生物科技主题ETF

华安恒生生物科技ETF

天弘国证生物医药ETF

标普新兴亚太 ETF - SPDR

美国制药 ETF - iShares

2 倍做多纳斯达克生物技术 ETF - ProShares

华夏恒生生物科技ETF(QDII)

iShares MSCI新兴市场ETF

医疗业 ETF - SPDR

富国恒生港股通创新药及医疗保健ETF

WisdomTree新兴市场高收益股票基金

易方达沪深300医药ETF

Dimensional Emerging Markets Value ETF

iShares安硕核心MSCI新兴市场ETF

动态生物技术与基因组 ETF - Invesco

基因改革 ETF - ARK

华宝恒生港股通创新药精选ETF

标普生物技术 3 倍做多 - Direxion

招商中证生物科技主题ETF

BlackRock, Inc.

Schwab新兴市场股票ETF

易方达中证生物科技主题ETF

博时恒生港股通创新药精选ETF

医药突破 ETF - ALPS

创新药

生物科技ETF基金

华夏印度-R

Avantis Emerging Markets Value ETF

博时恒生医疗保健(QDII-ETF)

纽交所高增长板生物技术指数 ETF - First Trust

标普全球医疗股指数 ETF - iShares

香港医药

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

易方达恒生港股通创新药ETF

iShares MSCI Emerging Mkts Val Fac ETF

标普生物技术 3 倍做空 - Direxion

新兴市场亚洲 MSCI ETF - iShares

Invesco Nasdaq Biotechnology ETF

广发中证香港创新药(QDII-ETF)

iShares MSCI新兴市场综合因素ETF

SPDR新兴市场投资组合ETF

华夏印度-U

2026 年应该在哪里进行投资？PL Capital 的专家为您解读最佳投资选择